Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs vinorelbine + cisplatin as adjuvant therapy in EGFR‑mutant stage II–IIIA NSCLC after surgery
CTR20150304Phase 3Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in EGFR-mutated non-small cell lung cancer, sponsored by Betta Pharmaceuticals. Started Jun 2015; status: active.
02
Drugs
icotinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on CTR20150304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150304.